LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Strona główna・Stock List・ESPERION THERAPEUTICS INC

ESPERION THERAPEUTICS INC

Open

Sector Healthcare

2 -1.48

Buy Sell

Overview

Share price change

24h

Current

Min

1.97

Max

2.04

Key metrics
By Trading Economics
Sales	32M
EPS	-0.5
Employees	240

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+376.35 upside

Dividends
By Dow Jones
Next Earnings	7 lis 2024

Market Stats
By TradingEconomics
Market Cap	-99M 516M
Previous open	3.48
Previous close	2

News Sentiment

By Acuity

70%

30%

338 / 390 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

2.03 / 2.125 Support & Resistance

ESPERION THERAPEUTICS INC Chart

Past performance is not a reliable indicator of future results.

Related News

25 mar 2024, 15:18 UTC

Major Market Movers

Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol

22 mar 2024, 15:34 UTC

Major Market Movers

Esperion Therapeutics Gets CHMP Positive Opinion for Cholesterol Medications

Peer Comparison

Price change

ESPERION THERAPEUTICS INC Forecast

Price Target

By TipRanks

376.35% upside

12 Months Forecast

Average 9.67 USD 376.35%

High 16 USD

Low 6 USD

Based on 4 Wall Street analysts offering 12 month price targets forESPERION THERAPEUTICS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to ESPERION THERAPEUTICS INC - Dist in the past 3 months.

Technical Score

By Trading Central

2.03 / 2.125Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

338 / 390 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). Its products include NEXLETOL, NILEMDO, NEXLIZET and NUSTENDI. NEXLETOL and NILEMDO are ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.